Hong Kong · Delayed Price · Currency is HKD Antengene Corporation Company Description
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally.
The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients.
Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors.
It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL).
In addition, the company’s pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager.
Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities.
Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 169 |
| CEO | Jay Mei |
Contact Details
Address: Zhongshan SOHO Plaza Shanghai, 200051 China | |
| Phone | 86 21 2356 6665 |
| Website | antengene.com |
Stock Details
| Ticker Symbol | 6996 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG039571008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay Mei M.D., Ph.D. | Founder, Chairman and Chief Executive Officer |
| Donald Andrew Lung J.D., M.B.A. | Chief Financial Officer and Executive Director |
| Rui Guo | Executive Officer |
| Eitan Liu M.Sc. | Chief Operating Officer |
| Shimin Sun M.D., M.P.H. | Corporate Vice President and Head of Clinical Enabling Functions and Operational Excellence |
| Thomas Karalis B.Sc. | Corporate Vice President and Head of Asia Pacific Region |
| Dr. Dirk Hoenemann | Vice President and Head of Medical Affairs for APAC and Early Clinical Development |
| Yang Cao C.F.A. | Joint Company Secretary |
| Wai Chiu Wong C.P.A., CTP, FCS | Joint Company Secretary |